ArticleCancer medicine2019

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study.

Guangjian Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.